pdf1 Publishing an article in European Urology magazine about the final findings in CDX’s clinical trial Post published:19/04/2017
pdf1 Engaging in a non-binding Memorandum of Understanding to invest in CardiacSense Post published:26/03/2017
pdf1 The company is examining investing between NIS 1 million and NIS 4 million in each of 1-3 companies in the field of biomed and life sciences Post published:23/01/2017
pdf1 Merchavia Holdings has completed the sale of the balance of shares of Libental, owned by Baruch Ofir Post published:12/12/2016
pdf1 Merchavia Holdings will complete the sale of shares in Libental to Baruch Ofir for NIS 1.8 million – continued Post published:01/12/2016
pdf1 The company will invest $500,000 in Juventas as part of an investment round for 0.65% of preferred shares Post published:06/09/2016
pdf1 The company will sell its holdings in Libental for about NIS 3.3 million Post published:01/09/2016
pdf1 The deal has been completed for the sale of the full rights in T.G.R. to Dashan Post published:29/05/2016
pdf1 Intermediary results in the trial of CDX’s product for early diagnosis of prostate cancer Post published:18/05/2016
